Redeye: Acconeer - New market strategy communicated
Redeye provides an update following Acconeer’s Q3 2024 results and updated go-to-market strategy. Net sales were below expectations while cost control remains solid, albeit partly driven by increased capitalised R&D y/y. Thus, EBITDA was better than anticipated. Inventory continues to come down, and the A2 will be finalised in 2025, with Redeye expecting low volumes in H2 2025 with ramp-up during 2026. Redeye reduces its estimates and fair value range.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/